INCY News and Press, Incyte Corporation From 07/11/23

2023-07-11 17:08:02 ET Gainers: Incyte  ( NASDAQ: INCY ) +4% . Veracyte ( VCYT ) +4% . Kronos ( KRON ) +3% . Applied Optoelectronics  ( AAOI ) +3% . GoodRx  ( GDRX ) +3% . Losers: Silk Road  ( SI...

Phase 3 TruE-AD3 Study met its primary endpoint Incyte (Nasdaq:INCY) today announced positive topline results from its randomized, vehicle-controlled, pivotal Phase 3 TRuE-AD3 study evaluating the safety and efficacy of ruxolitinib cream (Opzelura ® ) in children (age ≥...

2023-07-10 11:17:31 ET Summary Incyte Corporation's Q1 2023 financial performance showed mixed results, with a 10% rise in GAAP revenues but a significant drop in operating and net income. Despite a 23% stock decline over the past six months, Incyte demonstrated impressive growth ...

Opzelura ® is the first approved treatment in the United Kingdom (UK) to address repigmentation in non-segmental vitiligo Phase 3 data supporting the approval show treatment with ruxolitinib cream resulted in improved facial and total body repigmentation, sustained and contin...

2023-06-29 05:02:34 ET For further details see: Goldman adds 39 new stocks to its Sharpe Ratio basket with megacaps absent

2023-06-23 04:59:05 ET Goldman Sachs has rebalanced its ROE Growth basket of 50 stocks selected based on consensus expected return-on-equity growth over the next 12 months. The sector-neutral basket tapped 25 names in the rebalance. The median stock in the basket is projected to ach...

2023-06-01 05:16:01 ET Summary Baker Brothers' 13F portfolio value increased from $16.65B to $18.38B, with the largest five stakes in Seagen, Incyte, BeiGene, ACADIA Pharma, and Madrigal Pharma. The firm disposed of its stakes in Ascendis Pharma A/S and Horizon Therapeutics, while...

Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from across its oncology portfolio will be presented at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting held June 2-6 in Chicago, and at the European Hematology Association 2023 (EHA2023) Hyb...

2023-05-19 11:27:29 ET BofA Securities has initiated Xencor ( NASDAQ: XNCR ) with a buy highlighting its pipeline of protein therapeutics for cancer and inflammatory diseases. The firm has a $42 price target (~61% upside based on Thursday's close) in Friday morning trading. ...

Dr. Cagnoni joins Incyte’s Executive Team as President and Head of Research & Development Incyte (Nasdaq:INCY) today announced the creation of a new leadership role, appointing Pablo J. Cagnoni, M.D. President and Head of Research & Development (R&D) effective Jun...